Gallo PM, Chain RW, Xu J, Whiteman LM, Palladino A, Caricchio R, Costa-Reis P, Sullivan KE, Gallucci S
Autoantibodies; Erb-b2 Receptor Tyrosine Kinases; ErbB Receptors; Interferon-alpha; Lapatinib; Lupus Nephritis; Protein Kinase Inhibitors
Animals; Disease Models, Animal; Female; Fibrosis; Humans; Kidney; Lupus Erythematosus, Systemic; Mice; Mice, Inbred NZB; Quinazolines
Gallo PM, Chain RW, Xu J, Whiteman LM, Palladino A, Caricchio R, Costa-Reis P, Sullivan KE, Gallucci S. EGFR-ErbB2 dual kinase inhibitor lapatinib decreases autoantibody levels and worsens renal disease in Interferon a-accelerated murine lupus. Int Immunopharmacol. 2024 Oct 25; 140:112692.
EGFR-ErbB2 dual kinase inhibitor lapatinib decreases autoantibody levels and worsens renal disease in Interferon a-accelerated murine lupus.